ABSTRACT
BACKGROUND: Little is known about the pathogenesis and genetics of coronary artery ectasia (CAE). We studied eNOS gene intron 4a/b polymorphism in this patient population. METHODS: The study group included 30 patients with non-obstructive CAD besides CAE on coronary angiogram performed due to positive non-invasive diagnostic test results. The control group included 20 patients with normal coronary arteries. Agarose gel electrophoresis was used to identify eNOS gene polymorphisms. RESULTS: Only one coronary vessel was involved in most of the study cohort and the left anterior descending artery (LAD) was the most frequently involved vessel. The frequencies of eNOS gene phenotypes in the CAE group were 3.3% for"aa", 53.3% for"ab" and they were higher than in the control group. However, statistical significance was not reached (chi2 = 5.10, P = 0.08). When compared with the control group the presence of "a" type allele of eNOS gene was significantly more frequent in the CAE group (chi2 = 4.88, P = 0.027). By univariate analysis, eNOS gene polymorphism was correlated with CAE but this significance was attenuated after additional adjustment for potential confounding. CONCLUSION: Patients who have the "a" type allele of the eNOS gene may have an increased risk for CAE.
Subject(s)
Coronary Vessels/pathology , Introns , Nitric Oxide Synthase Type III/genetics , Polymorphism, Genetic , Dilatation, Pathologic/genetics , Female , Humans , Male , Middle AgedABSTRACT
BACKGROUND: Metabolic syndrome (MetS) is a leading risk factor for coronary artery disease (CAD) in women. Reduced paraoxonase 1 (PON1) activity may play a role in the pathogenesis of atherosclerosis through increased susceptibility to lipid peroxidation in patients with MetS. AIM: To examine whether there is a relationship between serum PON1 activity and MetS in women. METHOD: The study group consisted of 54 women with MetS. The NCEP ATP III guidelines were used to define MetS. The control group consisted of 65 women without MetS and CAD. All patients from the MetS group underwent coronary angiography. RESULTS: The PON1 activity and salt-stimulated PON1 activity were not significantly altered in women with MetS when compared to controls (p = 0.902, p = 0.877, respectively). There was no significant difference in PON1 activity (p = 0.159), and salt-stimulated PON1 activity (p = 0.139) between diabetics and non-diabetics. In the MetS group, patients with CAD (n = 16) had significantly reduced PON1 activity and salt-stimulated PON1 activity compared to MetS patients without CAD (p = 0.008 and p = 0.004, respectively). CONCLUSIONS: Serum PON1 activity is significantly reduced in women with CAD and MetS. MetS per se does not alter serum PON1 activities.
